clinical trial · NCT06112340
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics, Inc.·phase3·recruiting·n = 75
Thyroid Eye DiseaseGraves OrbitopathyEndocrine System DiseasesEye DiseasesThyroid Associated OphthalmopathyGraves OphthalmopathyThyroid DiseasesOrbital Diseaseslinsitinib
brief summary
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
started
Oct 11, 2023
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Feb 25, 2025
official title
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol